Rxsight Inc（RXST）股票分析

AI 分析 of Rxsight Inc (RXST)

持有

RxSight Inc is not a strong buy at the moment due to its current price of $4.80 being significantly below its 52-week high of $13.22 and the forward P/E ratio of 116.28 indicating high valuation concerns. The company is facing challenges with a net loss of $12.1 million reported for Q2 2026, which reflects ongoing financial difficulties. While the gross margin remains relatively strong at 76.72%, the withdrawal of full-year guidance and a projected EPS loss of $0.42 for the next earnings report suggest caution. The main risk is the high forward P/E ratio, which indicates that the stock may be overvalued given its current financial performance.

估值指標

Rxsight Inc（RXST）目前預期本益比為 116.28，5 年平均預期本益比為 -1.74。

預期本益比

高估

5 年均值 P/E

-1.74

目前P/E

116.28

高估

64.20

低估

-67.68

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-23.64

目前EV/EBITDA

-3.28

高估

5.29

低估

-52.56

預期股價營收比

低估

5 年均值 P/S

6.83

目前P/S

1.28

高估

10.78

低估

2.89

Alphio AI 對 RXST 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%RXST

$29.72

情境價格

基

基準

基準 · 50%RXST

$25.46

情境價格

悲

悲觀

悲觀 · 25%RXST

$19.14

情境價格

持有 RXST 的大戶

N

No Street GP LP

+ 持有RXST

-3.80%

3個月報酬率

RXST 常見問題 —— 由 Alphio AI 解答

RxSight, Inc. is a commercial-stage medical technology company engaged in providing customized vision to patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is composed of RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and related accessories. The LAL is an intraocular lens (IOL) made from the silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (UV) light patterns generated by the LDD. Its LAL uses a silicone formulation that enables changing the mechanical and optical properties of the lens following implantation. The LDD uses software and algorithms to deliver a short UV light exposure treatment that polymerizes specific portions of the lens and allows doctors to adjust spherical and cylindrical refraction. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

RxSight Inc is not a strong buy at the moment due to its current price of $4.80 being significantly below its 52-week high of $13.22 and the forward P/E ratio of 116.28 indicating high valuation concerns. The company is facing challenges with a net loss of $12.1 million reported for Q2 2026, which reflects ongoing financial difficulties. While the gross margin remains relatively strong at 76.72%, the withdrawal of full-year guidance and a projected EPS loss of $0.42 for the next earnings report suggest caution. The main risk is the high forward P/E ratio, which indicates that the stock may be overvalued given its current financial performance.